长效氟轻松玻璃体内植入剂或全身皮质类固醇治疗非感染性葡萄膜炎患者的纵向视力相关生活质量
本研究基于多中心类固醇治疗试验及随访研究的随机对照数据,评估非感染性葡萄膜炎患者3年内视力相关生活质量(NEI-VFQ-25)变化。植入剂组(129例)与全身治疗组(126例)3年评分均显著改善(分别+11.9分和+9.0分,交互P=0.21),植入剂组前6个月快速改善后稳定,全身组则逐步改善;仅植入剂组初始视力差者可克服基线缺陷。
要点
- 植入剂组与全身治疗组3年NEI-VFQ-25评分均显著改善,组间交互无显著差异(P=0.21)。
- 植入剂组前6个月快速改善后稳定,全身治疗组呈持续逐步改善。
- 仅植入剂组初始视力低于20/40者3年末可缩小与初始视力20/40或更好者的差距(差异-7分,P=0.081)。
核心结论
- 两种治疗组NEI-VFQ-25评分均显著改善,但植入剂组改善即时而全身治疗组改善渐进。
- 较差的基线视力功能与初始NEI-VFQ-25评分较低显著相关。
- 仅植入剂组中初始视力较差者在3年末能够克服其初始缺陷。
研究设计与样本
- 采用随机对照试验数据的队列研究,纳入多中心类固醇治疗试验及随访研究中活动性或近期活动性中间葡萄膜炎、后葡萄膜炎或全葡萄膜炎患者。
- 分析随机化后前3年每半年评估的25项国家眼科研究所视觉功能问卷(NEI-VFQ-25)数据,按 assigned treatment 分层(129例植入剂 vs 126例全身治疗)。
- 采用广义估计方程评估基线视功能(视力和视野)、人口学及疾病特征的影响。
主要发现
- 植入剂组3年NEI-VFQ-25评分改善11.9分(95%CI 8.6-15.2;P<0.001),全身治疗组改善9.0分(95%CI 5.6-12.3;P<0.001),交互P=0.21。
- 植入剂组前6个月大幅改善后评分稳定,全身治疗组随访期间持续改善。
- 两组中基线视力与视野较差均与初始NEI-VFQ-25评分较低相关;全身治疗组此差异贯穿随访全程。
- 植入剂组中初始视力低于20/40者NEI-VFQ-25评分额外改善,与初始视力20/40或更好者差距为-7分(95%CI -15.0至0.9),差异有临床意义但未达统计学显著(P=0.081)。
- 敏感性分析结果显示相似模式。
关键数值与推荐
- 主要结局为随机化后3年内NEI-VFQ-25综合评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate longitudinal vision-related quality of life (VRQoL) in patients with noninfectious uveitis. DESIGN: Cohort study using randomized controlled trial data. PARTICIPANTS: Patients with active or recently active intermediate uveitis, posterior uveitis, or panuveitis enrolled in the Multicenter Steroid Treatment Trial and Follow-up Study. METHODS: Data from the 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) for the first 3 years after randomization were evaluated semiannually. Analyses were stratified by assigned treatment (129 implants vs. 126 systemic therapies) because of substantial differences in the trajectories of VRQoL. The impact of baseline measurements of visual function (visual acuity and visual field), demographics, and disease characteristics was assessed using generalized estimating equations. MAIN OUTCOME MEASURES: Primary outcome was the NEI-VFQ-25 composite score over 3 years after randomization. RESULTS: Individuals in both treatment groups showed similar improvement in NEI-VFQ-25 scores after 3 years of follow-up (implant: 11.9 points; 95% confidence interval [CI], 8.6-15.2; P < 0.001; systemic: 9.0 points; 95% CI, 5.6-12.3; P < 0.001; P = 0.21 for interaction). Individuals in the implant group showed a substantial improvement during the first 6 months followed by stable scores, whereas individuals in the systemic group showed a steady improvement over the course of follow-up. Worse initial visual acuity and visual fields were associated with lower initial NEI-VFQ-25 scores for both treatment groups. In the systemic group, these differences were maintained throughout follow-up. In the implant group, individuals with initial visual acuity worse than 20/40 showed additional improvement in NEI-VFQ-25 score to come within -7 points (95% CI, -15.0 to 0.9) of those with visual acuity 20/40 or better initially, a clinically meaningful but not statistically significant difference (P = 0.081). Results based on sensitivity analyses showed similar patterns. CONCLUSIONS: Both treatment groups demonstrated significant improvements in NEI-VFQ-25 scores; however, the improvement was immediate for the implant group as opposed to gradual for the systemic group. Poorer visual function was associated significantly with initial differences in NEI-VFQ-25 scores. However, only individuals in the implant group with poor visual acuity were able to overcome their initial deficits by the end of 3 years.
引用
- Sugar EA, Venugopal V, Thorne JE, et al. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy. Ophthalmology. 2017. PMID: 28624167. doi:10.1016/j.ophtha.2017.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。